Results 181 to 190 of about 45,837 (320)
Summary Immunodiagnostic systems for on‐site screening are increasingly in demand but require expensive reagents such as chemically modified antibodies. To obtain biomolecules as ready‐to‐use reagents for diagnostics, new recombinant fluorescent immunoglobulins G were generated by fusion of the heavy chain of a monoclonal antibody, 5H3, to two ...
Ramona Sterpa +5 more
wiley +1 more source
RAPPID-M: A Mix-and-Measure Bioluminescent Sandwich Immunoassay Based on Generic Antibody-Binding Protein M. [PDF]
Swietlikowska A +4 more
europepmc +1 more source
ABSTRACT Mucosal vaccination for COVID‐19 to boost preexisting though insufficient systemic and local/mucosal immunity remains an attractive prospect but there are currently no licensed mucosal vaccines against this infection. Here, using a plant expression system, we developed a novel mucosal vaccine platform for respiratory viruses and demonstrated ...
Mi‐Young Kim +13 more
wiley +1 more source
Identification of engineered IMGT Fc variants in IMGT/mAb-DB, a database of therapeutic antibodies and fusion proteins. [PDF]
Manso T +8 more
europepmc +1 more source
Engineering of an Fc-specific monovalent protein G for the light-controlled affinity purification of antibodies. [PDF]
Mayrhofer P, Skerra A.
europepmc +1 more source
Clinical implications of imlifidase interference in antibody screening and transfusion management
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani +2 more
wiley +1 more source

